在研产品线
截止至2016年1月

百时美施贵宝公司拥有业内最创新的产品线之一。

一期临床 二期临床 三期临床 上市产品开发
  • Anti-Fucosyl GM1 (oncology)
  • BET Inhibitor (oncology)
  • Ulocuplumab(Anti-CXCR4) (oncology)
  • Anti-HER2 (oncology)
  • Mesothelin-ADC (oncology)
  • Anti-CD40L (immunoscience)
  • TYK2 Inhibitor (immunoscience)
  • Anti-CD40 (immunoscience)
  • Anti-PD-L1 (immunoscience)
  • BTK Inhibitor (immunoscience)
  • Anti-CSF1R (immuno-oncology)
  • Urelumab(Anti-CD137) (immuno-oncology)
  • Lirilumab(Anti-KIR) (immuno-oncology)
  • Anti-GITR (immuno-oncology)
  • Anti-LAG3 (immuno-oncology)
  • Anti-Myostatin (genetically defined diseases)
  • Anti-eTau (genetically defined diseases)
  • PEG-FGF21 (2) (fibrotic diseases)
  • Galectin-3 Inhibitor (fibrotic diseases)
  • PAR4 Antagonist (cardiovascular)
  • Factor XIa Inhibitors (cardiovascular)
  • Lulizumab(Anti-CD28) (immunoscience)
  • PEG-FGF21 (1) (fibrotic diseases)
  • LPA1 Antagonist (fibrotic diseases)
  • Pentraxin-2 (fibrotic diseases)
  • Nitroxyl Donor (cardiovascular)
  • IKur Inhibitor (cardiovascular)
  • PROSTVAC (immuno-oncology)
  • SPRYCEL® (dasatinib) (oncology)
  • Abatacept (immunoscience)
  • Belatacept (immunoscience)
  • Ipilimumab (immuno-oncology)
  • Elotuzumab (immuno-oncology)
  • Nivolumab (immuno-oncology)
  • ELIQUIS® (apixaban) (cardiovascular)

一期临床– 在少数人群中进行药物安全研究的临床试验。

二期临床– 在少数具有某种研究病症的病患中,进行某种在研药品的药物剂量、安全和药效的临床试验。

三期临床–在广泛的具有某种研究病症的人群中进行的某种在研药品的安全和药效的临床试验。

上市产品开发–针对已经在某个市场上市的产品,研究新的用法、配方的临床试验。